Darwinian, I just checked out N8. They are also working on prophylactic applications by coating their antibiotic on medical devices. From their website:
"Infections are a leading cause of death and illness worldwide. With the rapid rise of drug-resistant bacteria, nearly 70 percent of infections in the U.S. are now drug resistant, making the problem one of the most serious in the medical field. Hospital-acquired infections and healthcare-associated infections (HAIs) are a large and growing problem and cost the U.S. healthcare system $33 billion annually. They are estimated to affect more than 6 million persons annually in the United States, European Union and Japan combined. Of the approximately 1.7 million HAIs in the United States annually, nearly 100,000 patients die from these infections and many more require extended hospitalization and medical treatment. HAIs can occur during any procedure that breaches the skin or introduces a foreign object into the body, including catheterization, intubation, intravenous procedures and the use of surgical implants and devices., which account for 70 percent of HAIs.
Many hospitalized patients are immunocompromised, and are thus at high risk for infections. Materials commonly used to manufacture medical devices, such as silicone, PVC, polyurethane, stainless steel and titanium, provide a breeding ground for microbes. Biofilms essentially function as a reservoir of infectious agents and are highly resistant to conventional antibiotics. In some cases the only way to treat a patient whose implanted or indwelling device has become colonized with biofilm and bacteria is to surgically remove the device, which is extremely costly and is associated with high morbidity and risk of re-infection."
No worries, CTIX is working on this too.
"Separately, Cellceutix is pleased to provide and update on the Material Transfer Agreement (MTA) disclosed in November 2014 with a division of one of the largest U.S. pharmaceutical companies (the “Pharma”) for testing Brilacidin as a component of certain implanted devices as a means to prevent infection. Cellceutix has been advised that initial testing is encouraging. The Pharma has requested an extension to the MTA with an additional order to conduct further analysis of Brilacidin for this prophylactic application. The MTA does not cover the pharmaceutical use of Brilacidin for treatment of infections or other diseases. A final contract can only be entered into if and when Brilacidin receives Food and Drug Administration (FDA) approval.
“We feel the MTA extension and add-on order for additional research by such an esteemed organization is further validation of the potential of Brilacidin. These types of collaborations are important in expanding our defensin-mimetic drug discovery program in new verticals and we look forward to results from their testing in the future,” concluded Dr. Jorgensen."
http://cellceutix.com/cellceutix-announces-br...c8PUJ.dpuf
Since the initial result is encouraging, it tells me that the BP is seeing anti-biofilm properties of Brilacidin.
"Infections are a leading cause of death and illness worldwide. With the rapid rise of drug-resistant bacteria, nearly 70 percent of infections in the U.S. are now drug resistant, making the problem one of the most serious in the medical field. Hospital-acquired infections and healthcare-associated infections (HAIs) are a large and growing problem and cost the U.S. healthcare system $33 billion annually. They are estimated to affect more than 6 million persons annually in the United States, European Union and Japan combined. Of the approximately 1.7 million HAIs in the United States annually, nearly 100,000 patients die from these infections and many more require extended hospitalization and medical treatment. HAIs can occur during any procedure that breaches the skin or introduces a foreign object into the body, including catheterization, intubation, intravenous procedures and the use of surgical implants and devices., which account for 70 percent of HAIs.
Many hospitalized patients are immunocompromised, and are thus at high risk for infections. Materials commonly used to manufacture medical devices, such as silicone, PVC, polyurethane, stainless steel and titanium, provide a breeding ground for microbes. Biofilms essentially function as a reservoir of infectious agents and are highly resistant to conventional antibiotics. In some cases the only way to treat a patient whose implanted or indwelling device has become colonized with biofilm and bacteria is to surgically remove the device, which is extremely costly and is associated with high morbidity and risk of re-infection."
No worries, CTIX is working on this too.
"Separately, Cellceutix is pleased to provide and update on the Material Transfer Agreement (MTA) disclosed in November 2014 with a division of one of the largest U.S. pharmaceutical companies (the “Pharma”) for testing Brilacidin as a component of certain implanted devices as a means to prevent infection. Cellceutix has been advised that initial testing is encouraging. The Pharma has requested an extension to the MTA with an additional order to conduct further analysis of Brilacidin for this prophylactic application. The MTA does not cover the pharmaceutical use of Brilacidin for treatment of infections or other diseases. A final contract can only be entered into if and when Brilacidin receives Food and Drug Administration (FDA) approval.
“We feel the MTA extension and add-on order for additional research by such an esteemed organization is further validation of the potential of Brilacidin. These types of collaborations are important in expanding our defensin-mimetic drug discovery program in new verticals and we look forward to results from their testing in the future,” concluded Dr. Jorgensen."
http://cellceutix.com/cellceutix-announces-br...c8PUJ.dpuf
Since the initial result is encouraging, it tells me that the BP is seeing anti-biofilm properties of Brilacidin.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
